SGYP - 1) Plecanatide might be submitted to the FDA for approval by the end of this year. 2) The drug has the same MOA as Ironwoods' approved drug Linzess with apparently about half the diarrhea. 3) Synergy owns 100% of plceanatide while Ironwood owns around 50% of Linzess. 4) Synergy has patent protection on plecanatide until 2031. 5) Ironwood was rumored to have recently turned down an offer of $30 and Synergy is rumored to be on the block. Am I the only one here invested in or following this equity? Andy
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.